Curis Inc (NASDAQ: CRIS)

Sector: Healthcare Industry: Biotechnology CIK: 0001108205
Market Cap 10.98 Mn
P/B -0.75
P/E -0.30
P/S 0.94
ROIC (Qtr) 281.36
Div Yield % 0.00
Rev 1y % (Qtr) 8.36
Total Debt (Qtr) 1.97 Mn
Debt/Equity (Qtr) -0.13
Add ratio to table...

About

Investment thesis

Bull case

  • Healthy cash reserves of 9.05M provide 7.37x coverage of short-term debt 1.23M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 18.66M provides 9.48x coverage of total debt 1.97M, indicating robust asset backing and low credit risk.
  • Long-term investments of 544000 provide solid 0.74x coverage of long-term debt 740000, indicating strategic financial planning.
  • Retained earnings of (1.27B) represent substantial 86.23x of equity (14.69M), indicating strong internal capital generation.
  • Robust R&D investment of 31.40M at 2.16x of SG&A 14.52M demonstrates strong commitment to innovation and future growth.

Bear case

  • Investment activities of (428000) provide weak support for R&D spending of 31.40M, which is -0.01x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (30.09M) shows concerning coverage of stock compensation expenses of 4.50M, with a -6.68 ratio indicating potential earnings quality issues.
  • Operating earnings of (36.56M) show weak coverage of depreciation charges of 1.39M, with a -26.36 ratio indicating high capital intensity and potential reinvestment needs.
  • Free cash flow of (30.09M) represents just -4.72x of debt issuance 6.38M, suggesting concerning reliance on leverage rather than internal cash generation for growth.
  • Other non-current liabilities of 21.68M represent a high 1.16x of tangible assets 18.66M, suggesting significant long-term obligations without clear asset backing.

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,204.25 Bn -1,306.67 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 486.51 Bn 7,097.20 97.84 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 122.05 Bn 30.87 10.17 1.85 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 83.00 Bn 18.42 5.79 2.71 Bn
5 ARGX Argenx Se 50.78 Bn 33.71 26,480.10 -
6 ALNY Alnylam Pharmaceuticals, Inc. 43.66 Bn 139.17 11.76 2.97 Bn
7 BNTC Benitec Biopharma Inc. 43.61 Bn -941.82 0.00 0.00 Bn
8 INSM INSMED Inc 28.88 Bn -24.40 64.61 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.11 11.06
EV to Cash from Ops. EV/CFO -0.10 26.32
EV to Debt EV to Debt 1.60 762.61
EV to EBIT EV/EBIT -0.09 -13.49
EV to EBITDA EV/EBITDA -0.10 8.61
EV to Free Cash Flow [EV/FCF] EV/FCF -0.10 25.66
EV to Market Cap EV to Market Cap 0.29 203.37
EV to Revenue EV/Rev 0.27 156.31
Price to Book Value [P/B] P/B -0.75 20.59
Price to Earnings [P/E] P/E -0.30 -0.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 -12.64
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.14
Interest Coverage Int. cover (Qtr) 0.00 956.66
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 0.00 7.87
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) -56.60 753.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 19.63 -57.63
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 28.66 8.83
EBIT Growth (1y) % EBIT 1y % (Qtr) 19.63 -67.21
EBT Growth (1y) % EBT 1y % (Qtr) 19.63 -23.74
EPS Growth (1y) % EPS 1y % (Qtr) 54.63 -7.02
FCF Growth (1y) % FCF 1y % (Qtr) 25.68 -40.48
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 14.46 264.51
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.42 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 0.45 3.92
Current Ratio Curr Ratio (Qtr) 0.70 7.33
Debt to Equity Ratio Debt/Equity (Qtr) -0.13 0.48
Interest Cover Ratio Int Coverage (Qtr) 0.00 956.66
Times Interest Earned Times Interest Earned (Qtr) 0.00 956.66
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -301.90 -17,888.70
EBIT Margin % EBIT Margin % (Qtr) -313.79 -18,246.34
EBT Margin % EBT Margin % (Qtr) -313.79 -19,108.08
Gross Margin % Gross Margin % (Qtr) 99.50 -10.30
Net Profit Margin % Net Margin % (Qtr) -313.80 -19,056.96